Cross‑Listing and ADRs: How UK Stocks Trade in New York (and Vice Versa)
When AstraZeneca decided to upgrade its New York presence in 2026, it did not leave London – it added another front door for investors. That move captures how cross‑listing and American Depositary Receipts (ADRs) now let UK companies tap deep US liquidity without abandoning home markets.
In February 2026, AstraZeneca announced that its shares would begin trading on the New York Stock Exchange, moving from a Nasdaq ADR structure to a full NYSE listing under the ticker AZN. The company said the shift would give “equal weight” to its UK, Swedish and US listings and better reflect the growing importance of the US, which accounts for nearly half its earnings. One practical benefit: US investors will be able to buy AstraZeneca shares without paying UK stamp duty, a transaction tax that still applies to trading on the London Stock Exchange.
The broader trend has been underway for years. Bloomberg data cited in the same article show that trading volumes for ADR programmes of 20 FTSE 100 companies increased by more than 80% between 2019 and 2024, while their London volumes rose less than 8%. AstraZeneca’s own ADR trading was up 34% over that five‑year period, compared with sub‑8% growth in London activity. Other UK names such as Barclays, Diageo, British American Tobacco and GSK also saw ADR volumes double or more, highlighting how US investors increasingly access UK corporates through dollar‑denominated instruments on US venues.
AIG’s note on “UK Public Companies and US Securities Class Actions” underscores how widespread ADR usage has become. It estimates that over 200 UK companies have Level I ADRs available for purchase in the US, most of them trading over-the-counter rather than on national exchanges. Level I ADRs require less onerous registration than full exchange listings but still bring US securities‑law exposure, including potential class‑action risk. For boards considering a cross-listing, Freshfields warns that index “domesticity” rules mean it is not possible to be a constituent of major UK and US indices simultaneously; companies must weigh the benefits of US index inclusion against the loss of FTSE membership and any forced selling that might follow.
In practical terms, cross‑listing and ADRs affect how UK stocks trade in three ways:
They expand the investor base, making it easier for US institutions and retail buyers to build positions in pound‑denominated companies via dollar instruments.
They can shift liquidity: as AstraZeneca’s example shows, growth in ADR trading has outpaced London activity for many names, raising questions about the relative importance of home-market volumes over time.
They introduce regulatory and legal complexity, including US disclosure standards and class‑action exposure, which boards must manage carefully.
US companies listing in London face a mirror-image set of issues: CREST settlement, eligibility for FTSE indices, and whether a UK line brings enough incremental demand to justify the extra cost. For now, the flow is still predominantly one-way – UK and other non-US companies tapping US capital via ADRs and secondary listings – but the underlying theme is the same: global blue-chips increasingly treat listing venues as channels into different investor pools, not as mutually exclusive homes.